Bespak launch UniDose
UniDose DP, an innovative dry powder nasal device capable of delivering an accurate single dose of a wide range of therapeutic agents, has been launched commercially by Bespak.
UniDose DP, an innovative dry powder nasal device capable of delivering an accurate single dose of a wide range of therapeutic agents, has been launched commercially by Bespak.
Designed to provide a consistent, reproducible delivery of powder, Unidose DP offers a more than 90% delivery efficiency of the metered dose in a single actuation. Suitable for commercial development by pharmaceutical and generics companies, it is an ideal alternative delivery mechanism for the accurate administration of a range of formulations including proteins, peptides and vaccines.
Unidose DP is positioned to meet the emerging needs of the nasal drug delivery market. Aggressive growth of the market for nasally administered drugs is forecast to continue with the development of more protein and peptide based therapies. Furthermore, the phase out of harmful CFC propellants will continue the shift towards alternative methods of delivery such as propellant free, powder and liquid based devices.
Bespak is also able to offer pharmaceutical partners a range of device development and testing skills including specialist drug deposition modelling of the nasal cavity. Recognising that the outward design of devices should reflect the needs of the user and dosing regime, it is able to vary the design of the Unidose DP device and recommend suitable administration techniques and powder characteristics to target specific areas in the nasal cavity for maximum therapeutic effect.